New analysis shows fewer years of life lost to cancer

January 15, 2014

Since the enactment of the National Cancer Act in 1971, the U.S. has spent hundreds of billions of dollars in cancer research and treatment. And yet, the cancer mortality rate—the historic benchmark of progress—has only declined modestly while the mortality rates of other leading causes of death have declined substantially. This difference has led many to question whether we've made progress in the 'War on Cancer'. The answer is definitively yes according to Norris Cotton Cancer Center research published Monday in the Journal of Clinical Oncology.

"Our findings show that we have made steady progress against the burden of many cancers for decades," said lead author Samir Soneji, PhD, assistant professor for Geisel School of Medicine at Dartmouth and the Dartmouth Institute for Health Policy and Clinical Practice. "We have underestimated the progress because, as fewer and fewer people die from heart disease, stroke, and accidents, more and more people are living longer and having more years in which to develop and die from cancer."

According to Soneji the accuracy of existing measurements for the nation's progress against the burden of cancer are limited because they reflect progress against other diseases. Soneji and his colleagues Hiram Beltrán-Sánchez, PhD, and Harold C. Sox, MD, measured the effect of cancer prevention, screening, and treatment on the burden of while taking account of the increased incidence of cancer because people are living longer as a result of progress against other leading causes of death.

To solve a problem first identified by the National Cancer Institute (NCI) 20 years ago, Dartmouth cancer researchers started with a measure of the burden of cancer mortality called the years of life lost due to cancer, which reflects how much longer we might expect to live if cancer did not exist. They then separated the favorable effect of advancements in cancer care from the unfavorable effect on due to advancements in the care of other diseases, notably cardiovascular disease.

"We estimate how the years of life lost from cancer are directly affected by cancer mortality and indirectly affected by increased cancer incidence because of greater longevity due to improvements in primary prevention, detection, and treatment of other disease," said Soneji. With this approach cancer control researchers at Norris Cotton Cancer Center were able to measure how much progress the U.S. has made against the burden of cancer mortality in America.

Soneji's research concluded that the decrease in lung cancer between 1985 and 2005 tripled their contribution to reducing the years of life lost due to cancer. Yet not all of this progress was actually realized because other-cause mortality rates also decreased. The resulting increase in life expectancy and its consequent increase in lung cancer incidence partially offset this progress. "The decline in cigarette smoking, which began in the 1960s, is almost certainly the main reason the burden of lung cancer mortality declined," said Soneji.

Authors Soneji, Beltrán-Sánchez, and Sox also found consistent progress in reducing the burden of colorectal cancer mortality since 1985. More recent, but less consistent, progress has been made in reducing the burden on prostate and breast cancer deaths.

"Our approach reveals more accurately the aggregate contribution of cancer prevention, screening, and treatment on progress against cancer," said Soneji.

To date, survival time and mortality rates have been the leading population-level measures of cancer burden. These measures assess the effect of prevention, screening, and treatment on cancer, but they fail to account for changes in other-cause mortality rates. In contrast, Soneji and his colleagues used a more comprehensive measure that accounts for both changes in and changes in other-cause mortality rates. By accounting for progress against other leading causes of death, researchers can now more accurately assess progress against cancer. Whether historical progress in cancer continues in the future depends, in large part, on whether cigarette smoking continues to decline and effective screening detects earlier and more treatable stages of .

Explore further: Cancer Statistics 2014: Death rates continue to drop

Related Stories

Cancer Statistics 2014: Death rates continue to drop

January 7, 2014
The annual cancer statistics report from the American Cancer Society finds steady declines in cancer death rates for the past two decades add up to a 20 percent drop in the overall risk of dying from cancer over that time ...

Cancer trends tell tale of insufficient prevention

November 4, 2013
Australians are now developing cancer at slightly higher rates but dying of the disease less often, according to University of Sydney research published in the Medical Journal of Australia (MJA).

CDC: breast cancer mortality higher in black women

November 15, 2012
(HealthDay)—With earlier detection and better treatment, the mortality rate from breast cancer has fallen over the last two decades; black women, however, still die from the disease at a disproportionately higher rate than ...

Total cancer death rate drops but progress slow on 'forgotten cancers'

August 20, 2013
Australia's mortality rate for all cancers has dropped 28% in 20 years, new figures show, but progress has been slow in the fight against thyroid and pancreatic cancer, while the death rate from liver cancer has skyrocketed.

Cancer cases up 11%, breast cancer by a fifth: WHO

December 12, 2013
The number of new cancer cases around the globe jumped by 11 percent in a five-year period, reaching 14.1 million in 2012, with breast cancer increasing by one-fifth, the UN health agency said Thursday.

American cancer society celebrates 100 years of progress

May 22, 2013
(HealthDay)—The American Cancer Society, which is celebrating on Wednesday a century of fighting a disease once viewed as a death sentence, is making a pledge to put itself out of business.

Recommended for you

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

How CD44s gives brain cancer a survival advantage

July 19, 2017
Understanding the mechanisms that give cancer cells the ability to survive and grow opens the possibility of developing improved treatments to control or cure the disease. In the case of glioblastoma multiforme, the deadliest ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.